Intravesical Recombinant BCG (Bacillus Calmette Guerin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; BCG vaccine (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
Indications Bladder cancer
Focus Therapeutic Use

11 Mar 2024 Planned number of patients changed from 5 to 46.
27 Jan 2024 According to the trial design presented at the 2024 Genitourinary Cancers Symposium, an interim safety analysis will be performed after the first 12 pts have completed neoadjuvant treatment, and an interim efficacy analysis will be performed after the first 21 pts have undergone surgery. Accrual to the study is currently ongoing.
27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com